Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aclaris Therapeutics ( (ACRS) ) has provided an update.
On June 30, 2025, Aclaris Therapeutics updated its corporate overview presentation, highlighting its robust clinical pipeline and financial outlook. The company is advancing several drug candidates, including bosakitug, ATI-052, and ATI-2138, with ongoing clinical trials and expected data releases in 2025. Aclaris anticipates its current cash reserves will fund operations through the first half of 2028, with potential for additional non-dilutive financing. The announcement underscores Aclaris’ strategic positioning for growth and its commitment to developing innovative therapies for immuno-inflammatory diseases.
The most recent analyst rating on (ACRS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.
Spark’s Take on ACRS Stock
According to Spark, TipRanks’ AI Analyst, ACRS is a Neutral.
Aclaris Therapeutics is currently facing significant challenges, with a primary focus on its financial performance. The company’s lack of profitability and reliance on external financing are major concerns. The technical analysis further underscores negative momentum, although oversold indicators might suggest a potential short-term rebound. Valuation is unattractive due to negative earnings, and no significant earnings call data or corporate events are available to offset these issues.
To see Spark’s full report on ACRS stock, click here.
More about Aclaris Therapeutics
Aclaris Therapeutics operates in the biopharmaceutical industry, focusing on the discovery and development of novel therapies for immuno-inflammatory diseases. The company specializes in both small and large molecule therapeutics, with a pipeline that includes drug candidates targeting conditions such as atopic dermatitis, COPD, and asthma. Aclaris leverages its proprietary kinase small molecule discovery engine and has a strong track record in advancing biologics and small molecules to clinical development.
Average Trading Volume: 958,651
Technical Sentiment Signal: Sell
Current Market Cap: $159.2M
For an in-depth examination of ACRS stock, go to TipRanks’ Overview page.